AQST vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

AQST

67.1
AI Score
VS
AQST Wins

PCRX

58.6
AI Score

Investment Advisor Scores

AQST

67score
Recommendation
BUY

PCRX

59score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AQST PCRX Winner
Revenue 28.27M 369.77M PCRX
Net Income -30.92M 7.57M PCRX
Net Margin -109.4% 2.0% PCRX
Operating Income -12.43M 11.17M PCRX
ROE 54.6% 1.1% AQST
ROA -23.4% 0.6% PCRX
Total Assets 132.10M 1.24B PCRX
Cash 98.49M 205.88M PCRX
Debt/Equity -0.97 0.54 AQST
Current Ratio 7.19 5.04 AQST
Free Cash Flow -24.51M 79.08M PCRX

Relative Price Performance (Last 90 Days)

AQST 1M: -15.4% · 3M: +7.3% PCRX 1M: -5.2% · 3M: -1.5%

Current Technical Phase

AQST

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.3 · Price: $4.55

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $25.21

Fundamentals Snapshot

Metric AQST PCRX
Market Cap — —
Forward P/E -8.0 7.3
Trailing P/E — 71.5
Revenue (TTM) — —
Revenue Growth 0.4% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin -0.6% 0.1%
EPS -0.63 0.35
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, AQST is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.